EGFR and cancer: Previous studies indicated that the epithelial–mesenchymal transition regulator, Slug, confers resistance to EGFR-TKI therapy in lung adenocarcinoma patients and that interleukin (IL)-8 plays a role in the EGFR-TKI-resistance mechanism by regulating cancer stem cell properties [11,12].